Summit Therapeutics Inc. experienced a significant jump in its stock price following the announcement of a $2 billion strategic equity investment from AstraZeneca. This investment involves convertible preferred shares, representing a common stock price equivalent to $18.36 per share, which is a premium over the closing trading price on the day of the announcement. This substantial financial backing is seen as a strong validation of ivonescimab, Summit's investigational PD-1 / VEGF bispecific antibody.
Beyond the equity investment, the two companies are entering into a clinical collaboration to evaluate ivonescimab in combination with sonesitatug vedotin (sone-ve) for multiple gastrointestinal cancers. Sone-ve is a Claudin 18.2-targeting antibody-drug conjugate (ADC) that recently showed promising overall survival improvements in advanced gastric cancers. AstraZeneca will sponsor these combination studies, with both companies contributing their respective compounds and sharing costs, while retaining commercial rights to their individual molecules.
Furthermore, Summit and AstraZeneca plan to explore additional clinical trials combining ivonescimab with other AstraZeneca cancer medicines, including their extensive portfolio of ADCs. This broader collaboration aims to leverage ivonescimab's potential to enhance anti-cancer immunity and tumor microenvironment modulation. The agreement also specified that there would be no additional financial considerations such as milestones, royalties, or profit-sharing for these future studies.
This deal provides a crucial boost to Summit, a pre-revenue biotech firm that has been burning approximately $458 million annually. With $690 million in cash prior to this investment, Summit had an estimated 18 months of runway, leading to concerns about future capital raises. This $2 billion investment significantly strengthens Summit's financial position, potentially extending its runway and supporting ongoing Phase III trials for ivonescimab in non-small cell lung cancer and colorectal cancer.
